Search Results - "Kurebe, H"

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.

Authors: Edahiro R Kanazu M Kurebe H et al.

Source: PloS one [PLoS One] 2019 Jul 31; Vol. 14 (7), pp. e0220570. Date of Electronic Publication: 2019 Jul 31 (Print Publication: 2019).

Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report.

Authors: Kuge, Tomoki Okabe, Fukuko Yamamoto, Yuji et al.

Source: Thoracic Cancer. Jun2021, Vol. 12 Issue 12, p1935-1939. 5p.

Association between immune-related adverse events and therapeutic outcomes in patients with advanced non-small cell lung cancer treated with pembrolizumab: A retrospective study.

Authors: TALAB, TABARAK J. ALI SHAFI, FARHA A. JASIM, SABA M.

Source: World Academy of Sciences Journal. Sep/Oct2025, Vol. 7 Issue 5, p1-9. 9p.

Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.

Authors: Yano Y Kurebe H Edahiro R et al.

Source: PloS one [PLoS One] 2018 Aug 28; Vol. 13 (8), pp. e0203070. Date of Electronic Publication: 2018 Aug 28 (Print Publication: 2018).

Publication Type: Journal Article

Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Efficacy and safety of nanoparticle albumin‐bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non‐small cell lung cancer: A multicenter Phase 2 clinical trial.

Authors: Sonoda, Tomoaki Umeda, Yukihiro Demura, Yoshiki et al.

Source: Cancer Medicine. Jun2023, Vol. 12 Issue 12, p13041-13053. 13p.

Relocalization of Translation Termination and Ribosome Recycling Factors to Stress Granules Coincides with Elevated Stop-Codon Readthrough and Reinitiation Rates upon Oxidative Stress.

Authors: Makeeva, Desislava S. Riggs, Claire L. Burakov, Anton V. et al.

Source: Cells (2073-4409). Jan2023, Vol. 12 Issue 2, p259. 19p.

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies.

Authors: Sholl, Lynette M. Awad, Mark Roy, Upal Basu et al.

Source: Archives of Pathology & Laboratory Medicine. Jul2024, Vol. 148 Issue 7, p757-774. 18p.

Durvalumab‑induced type 1 diabetes mellitus in lung adenocarcinoma: A case report and literature review.

Authors: Dong, Huijing Li, Shengfu Peng, Yanmei et al.

Source: Oncology Letters. Jun2025, Vol. 29 Issue 6, pN.PAG-N.PAG. 1p.

Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression.

Authors: Uenami T Ishijima M Kanazu M et al.

Source: Annals of translational medicine [Ann Transl Med] 2018 Nov; Vol. 6 (22), pp. 444.

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: AME Publishing Company Country of Publication: China NLM ID: 101617978 Publication Model: Print Cited Medium: Print ISSN: 2305-5839 (Print) Linking ISSN: 23055839 NLM ISO Abbreviation: Ann Transl Med Subsets: PubMed not MEDLINE

SLU7: A New Hub of Gene Expression Regulation—From Epigenetics to Protein Stability in Health and Disease.

Authors: Gárate-Rascón, María Recalde, Miriam Rojo, Carla et al.

Source: International Journal of Molecular Sciences. Nov2022, Vol. 23 Issue 21, p13411. 19p.

Non‐small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune‐related adverse events in first‐line treatments with immune checkpoint inhibitors: A retrospective single‐center study

Authors: Akazawa, Yuki Yoshikawa, Aki Kanazu, Masaki et al.

Source: Thoracic Cancer. Sep2022, Vol. 13 Issue 17, p2450-2458. 9p.

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Authors: Alonso-García, Miriam Sánchez-Gastaldo, Amparo Muñoz-Fuentes, Miguel A. et al.

Source: Pharmaceuticals (14248247). May2022, Vol. 15 Issue 5, p533-533. 14p.

Nucleoli and Stress Granules: Connecting Distant Relatives.

Authors: Mahboubi, Hicham Stochaj, Ursula

Source: Traffic. Oct2014, Vol. 15 Issue 10, p1179-1193. 15p.

Embryotoxic and Teratogenic Effects of Norfloxacin in Pregnant Female Albino Rats.

Authors: Aboubakr, Mohamed Elbadawy, Mohamed Soliman, Ahmed et al.

Source: Advances in Pharmacological Sciences. 2014, p1-6. 6p.

Biological function and molecular mechanism of SRSF3 in cancer and beyond.

Authors: Xiong, Jian Chen, Yinshuang Wang, Weipeng et al.

Source: Oncology Letters. Jan2022, Vol. 23 Issue 1, pN.PAG-N.PAG. 1p.

Identifying factors for pembrolizumab eligibility in head and neck cancer.

Authors: Miyamaru S Murakami D Nishimoto K et al.

Source: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2025 Feb 07; Vol. 151 (2), pp. 67. Date of Electronic Publication: 2025 Feb 07.

Publication Type: Journal Article

Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression.

Authors: Prelaj, Arsela Pircher, Chiara Carlotta Massa, Giacomo et al.

Source: Cancers. Mar2021, Vol. 13 Issue 6, p1300. 1p.

The potential impact of RNA splicing abnormalities on immune regulation in endometrial cancer.

Authors: Cao M Yan J Ding Y et al.

Source: Cell death & disease [Cell Death Dis] 2025 Mar 03; Vol. 16 (1), pp. 148. Date of Electronic Publication: 2025 Mar 03.

Publication Type: Journal Article; Review

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE

Oncogenic SRSF3 in health and diseases.

Authors: Jia R Zheng ZM

Source: International journal of biological sciences [Int J Biol Sci] 2023 Jun 12; Vol. 19 (10), pp. 3057-3076. Date of Electronic Publication: 2023 Jun 12 (Print Publication: 2023).

Publication Type: Journal Article; Review; Research Support, N.I.H., Intramural

Journal Info: Publisher: Ivyspring International Country of Publication: Australia NLM ID: 101235568 Publication Model: eCollection Cited Medium: Internet ISSN: 1449-2288 (Electronic) Linking ISSN: 14492288 NLM ISO Abbreviation: Int J Biol Sci Subsets: MEDLINE

Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis.

Authors: Tang XY Shi AP Xiong YL et al.

Source: Frontiers in oncology [Front Oncol] 2021 Jul 22; Vol. 11, pp. 693321. Date of Electronic Publication: 2021 Jul 22 (Print Publication: 2021).

Publication Type: Journal Article; Review

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE